Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2009 Jan 24;7(8):874–881. doi: 10.1016/j.cgh.2009.01.004

Table 1.

Characteristics of Included Studies

Study Year Publication type N CD duration (y)a Anti-TNF agent % on IMb Median follow-up (wk) Patient-Yearsc % Drop out Number of NHL
RCT
 Colombel et al27 (P3/4) 2007 Abstract 905 6 CTZ NR 53 922.4 NR 0
 Colombel et al13 (OLE) 2007 Abstract 1169 NR ADA 46.6 58 1299 1 0
 Sandborn et al18 2007 Full 276 8.7 ADA 30.5 56 552 1.8 1
 Lemann et al15 2006 Full 57 4.8 IFX 100 52 57.0 3.5 0
 Schroder et al31 2006 Full 19 8.9 IFX 100 48 17.5 0 0
 Mantzaris et al14 2004 Abstract 45 NR IFX 53 60 51.9 0.04 0
 Sands et al3 2004 Full 282 11.5 IFX 34.4 54 292.8 0 0
 Hanauer et al2 2002 Full 573 8.2 IFX 29 54 595.0 0 0d
 Rutgeerts et al17 1999 Full 73 10.4 IFX 35 48 67.4 0 1
Cohort
 Lichtenstein et al7 2007 Abstract 3396 10.7 IFX 49 201 13,126 21 6
 Biancone et al32 2006 Full 404 9.5 IFX 53 109 846.8 0 0
 Doumit et al33 2004 Abstract 322 13.7 IFX 88.2 104 644 0 1
Case series
 Carbone et al21 2007 Full 34 NR IFX 48 52 159.5 0 0
 Peyrin-Biroulet et al36 2007 Full 52 11 ADA 71 52 52.0 0 0
 Hyder et al23 2006 Full 22 6 IFX 95 91 38.5 0 0
 Pacault et al40 2006 Abstract 137 NR IFX NR 150 395.2 NR 0
 Talbot et al24 2005 Full 21 6 IFX 57 87 35.1 0 0
 Choi et al22 2005 Full 13 8.3 IFX 84.6 57 14.3 0 0
 Ardizzone et al20 2004 Full 20 9 IFX 23.2 67 25.8 33 0
 Colombel et al35 2004 Full 500 8 IFX 85 74 711.5 0 1
 Rodrigo et al37 2004 Full 44 7.6 IFX 89 72 60.9 0 0
 Schroder et al38 2004 Full 12 11.5 IFX 100 57.6 13.3 0 0
 Seiderer et al19 2004 Full 92 8.4 IFX 82 113 199.9 0 0
 Ljung et al16 2003 Full 191 NR IFX 51 55 202.0 0 3
 Kinney et al25 2003 Full 117 13.3 IFX 48 52 117.0 9.6 0
 Cohen34 2000 Full 129 13.5 IFX 54 52 129.0 0 0

Abbreviations: IM, immunomodulator; N, total number exposed to anti-TNF; NR, not reported; P3/4, PRECISE 3/4; OLE, open label extension of GAIN and CHARM trials.

a

Disease duration based on best estimate from available data; mixed reporting of mean and median.

b

Patients taking concomitant IMs (azathioprine, 6MP, methotrexate) during study.

c

Calculated by converting follow-up time from weeks to years and multiplying by total N.

d

There was one NHL from Hanauer et al, but also reported in Ljung et al.